Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus*

2019/04/24 by S. Ständer, Sonja Ständer, Gil Yosipovitch +1 · 25 citations
Medicine · #Dermatology and Skin Diseases #Urticaria and Related Conditions #Asthma and respiratory diseases

paper · pdf · doi:10.1111/bjd.18025

Abstract

BACKGROUND: Chronic pruritus is a distressing symptom associated with various dermatological conditions and systemic diseases. Current treatment options are often inadequate, resulting in impaired quality of life for many patients. An understanding of the underlying mechanisms of itch across pruritic conditions is important for development of effective, targeted treatments for chronic pruritus. OBJECTIVES: R antagonism as a potential strategy for the treatment of chronic pruritus. METHODS: R in itch signalling. RESULTS: R antagonism disrupts itch signalling and reduces itch provide a rationale for targeting this pathway as a potential treatment of chronic pruritus across multiple diseases. CONCLUSIONS: R antagonists in the treatment of pruritus is provided.

Citations

• Microfacies, diagenesis, stable isotope geochemistry, and reservoir characterization of the Late Permian Khuff-C reservoir, southern Ghawar Field, Saudi Arabia

Cited by

• Calcium imaging of primary canine sensory neurons: Small-diameter neurons responsive to pruritogens and algogens. [europepmc]
• Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial. [europepmc]
• Itch and Cough - Similar Role of Sensory Nerves in Their Pathogenesis. [europepmc]
• Emerging Therapeutic Options for Chronic Pruritus. [europepmc]
• Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch. [europepmc]
• Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa. [europepmc]
• Neurokinin-1 Receptor Inhibition and Cough. [europepmc]
• Neurokinin 1 Receptor Antagonists for Pruritus. [europepmc]
• Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions. [europepmc]
• The Multifaceted Mas-Related G Protein-Coupled Receptor Member X2 in Allergic Diseases and Beyond. [europepmc]
• Connections between Immune-Derived Mediators and Sensory Nerves for Itch Sensation. [europepmc]
• Peripheral Mechanisms of Itch. [europepmc]
• Neurokinins and their receptors in the rat trigeminal system: Differential localization and release with implications for migraine pain. [europepmc]
• Critical Players and Therapeutic Targets in Chronic Itch. [europepmc]
• Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment. [europepmc]
• Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis. [europepmc]
• Neurotrophins: Neuroimmune Interactions in Human Atopic Diseases. [europepmc]
• Inflammation and Organ Injury the Role of Substance P and Its Receptors. [europepmc]
• Basophils in pruritic skin diseases. [europepmc]
• Mucosal neuroimmune mechanisms in gastro-oesophageal reflux disease (GORD) pathogenesis. [europepmc]
• From Compression to Itch: Exploring the Link Between Nerve Compression and Neuropathic Pruritus. [europepmc]
• Molecular and cellular mechanisms of itch sensation and the anti-itch drug targets. [europepmc]
• The role of neuropeptides in cutaneous wound healing: a focus on mechanisms and neuropeptide-derived treatments. [europepmc]
• Deciphering Pain and Pruritus in Keloids from the Perspective of Neurological Dysfunction: Where Are We Now? [europepmc]
• Prevalence and Mechanisms of Itch in Chronic Wounds: A Narrative Review. [europepmc]

Related

• Chronic pruritus: From pathophysiology to drug design
• Prurigo nodularis: new insights into pathogenesis and novel therapeutics
• Physiology and Pathophysiology of Itch
• The Role of Mast Cells in the Pathophysiology of Chronic Prurigo
• Polycythemia vera‐associated pruritus and its management